New Hampshire Medicaid and GLP-1s

What changed, and what the document says

1. GLP-1s for weight loss

   Not covered

   Not covered from January 1, 2026, when weight loss is the only reason for the prescription.

   “Per NH DHHS, effective January 1, 2026, New Hampshire Medicaid will no longer cover GLP-1 medications when prescribed solely for weight loss.”

   AmeriHealth Caritas New Hampshire — notice to Medicaid providers — October 10, 2025

2. What keeps coverage

   Covered

   Four conditions, named. If one of them is on the chart, the drug is still paid for.

   “Coverage will remain unchanged for members using GLP-1s as part of a treatment plan for other chronic health conditions such as the treatment of type 2 diabetes, major adverse cardiovascular events (MACE), severe obstructive sleep apnea and Metabolic Dysfunction-Associated Steatohepatitis (MASH).”

   AmeriHealth Caritas New Hampshire — notice to Medicaid providers — October 10, 2025

3. Which drugs

   Context

   Saxenda, Wegovy and Zepbound by name, and generics of them.

   “GLP-1 medications (such as Saxenda, Wegovy, and Zepbound and any generic versions) will no longer be reimbursed by Medicaid if prescribed exclusively for weight loss purposes.”

   AmeriHealth Caritas New Hampshire — notice to Medicaid providers — October 10, 2025

4. A second plan says the same

   Context

   A different managed-care plan told its members the same thing four days later. Two independent notices, one change.

   “Effective January 1, 2026, NH Healthy Families will no longer cover GLP-1 medications when prescribed solely for weight loss. These medications will continue to be covered when prescribed for other chronic health conditions.”

   NH Healthy Families — member newsroom notice — 10/14/25

5. The national picture

   Context

   New Hampshire is one of four states a national tracker names as having ended this coverage since October 2025.

   “Notably, KFF's 2025 Medicaid budget survey found 16 state Medicaid programs covered GLP-1s for obesity treatment as of October 2025; however, since then, four states (California, New Hampshire, Pennsylvania, and South Carolina) have eliminated coverage of GLP-1s for obesity treatment, likely reflecting recent state budget challenges and the significant costs associated with coverage.”

   KFF — Jan 16, 2026

Which of these companies serve New Hampshire?

Of the 284 companies we grade, 28 publish a list of the states they are licensed in. We checked 250 more and found no such list on any page we read; 6 we have not checked either way.

20 of those lists name New Hampshire: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, and MEDvidi. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.